[Longterm treatment of coronary heart disease with Segontin (author's transl)].
62 patients with coronary heart disease were treated with Segontin 60 mg for periods of 6 months to 8 years in a specialist internal medical practice. The average maintenance dose was 2 Segontin 60 mg dragees daily. Segontin 60 was distinguished by a high success rate under practice conditions with good tolerance at the same time. Because of its additional sympathicolytic antiarrhythmic and central sedative action, Segontin 60 is a particularly valuable preparation of the calcium antagonist series with which it also shares the circulation-promoting and coronary analge sic actions and economizing effect on the heart metabolism. It has proved itself very good for the treatment of angina pectoris conditions in patients with coronary heart disease. Moreover, Segontin 60 mg is the preparation of choice if the coronary heart disease is accompanied by tachyarrhythmic and hyperkinetic symptoms.
D000787:Angina Pectoris / Q000188:drug therapy; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D004341:Drug Evaluation; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008134:Long-Term Care; D011299:Prenylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013610:Tachycardia / Q000150:complications / Q000188:drug therapy
D001786:Blood Glucose; D011299:Prenylamine
Langzeitbehandlung der koronaren Herzkrankheit mit Segontin 60 mg